2022-11-11 18:06 | CC:RVX | Resverlogix Corp | 0.19 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-11-11 18:06 | CC:RVX | Resverlogix Corp | 0.19 | SEDAR MD & A815 | SEDAR MD & A |
2022-09-28 10:45 | CC:RVX | Resverlogix Corp | 0.205 | News Release200 | Resverlogix to focus apabetalone work on long COVID |
2022-08-22 10:08 | CC:RVX | Resverlogix Corp | 0.25 | News Release200 | Resverlogix publishes apabetalone data in journal |
2022-08-15 18:48 | CC:RVX | Resverlogix Corp | 0.27 | News Release200 | Resverlogix adds Kulikowski as chief scientific officer |
2022-08-12 19:09 | CC:RVX | Resverlogix Corp | 0.265 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-08-12 19:09 | CC:RVX | Resverlogix Corp | 0.265 | SEDAR MD & A815 | SEDAR MD & A |
2022-06-22 01:21 | CC:RVX | Resverlogix Corp | 0.26 | News Release200 | Resverlogix shareholders approve all AGM resolutions |
2022-06-08 10:20 | CC:RVX | Resverlogix Corp | 0.22 | News Release200 | Resverlogix talks BD2-selective BET inhibitor safety |
2022-05-13 18:09 | CC:RVX | Resverlogix Corp | 0.315 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-05-13 18:09 | CC:RVX | Resverlogix Corp | 0.315 | SEDAR MD & A815 | SEDAR MD & A |
2022-05-09 09:43 | CC:RVX | Resverlogix Corp | 0.345 | News Release200 | Resverlogix sets FDA meeting for apabetalone study |
2022-04-19 17:18 | CC:RVX | Resverlogix Corp | 0.44 | News Release200 | Resverlogix extends $6M (U.S.) debenture by one year |
2022-04-01 02:43 | CC:RVX | Resverlogix Corp | 0.47 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
2022-04-01 02:43 | CC:RVX | Resverlogix Corp | 0.47 | SEDAR MD & A815 | SEDAR MD & A |
2022-04-01 02:42 | CC:RVX | Resverlogix Corp | 0.47 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |
2022-03-17 10:06 | CC:RVX | Resverlogix Corp | 0.46 | News Release200 | Resverlogix publishes apabetalone data in journal |
2022-02-17 10:06 | CC:RVX | Resverlogix Corp | 0.73 | News Release200 | Resverlogix initiates Brazilian apabetalone trial site |